Myelodysplastic syndrome patient-derived xenografts: from no options to many.

According to the recently updated tumor classification by the World Health Organization, myelodysplastic syndrome (MDS) constitutes a heterogeneous group of blood disorders characterized by cytopenia and dysplasia in at least one of the myeloid lineages.[1][1] MDS is most common in the elderly and